Death receptors as targets in cancer - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Preprints, Working Papers, ... Year : 2014

Death receptors as targets in cancer


Anti-tumour therapies based on the use PARAs (pro-apoptotic receptor agonists), including TRAIL (TNF-Related Apoptosis inducing Ligand) or monoclonal antibodies targeting TRAIL-R1 or TRAIL-R2, have been disappointing so far, despite clear evidence of clinical activity and lack of adverse events for the vast majority of these compounds, whether combined or not with conventional or targeted anti-cancer therapies. This brief review aims at discussing the possible reasons for the lack of apparent success of these therapeutic approaches and at providing hints in order to rationally design optimal protocols based on our current understanding of TRAIL signalling regulation or resistance for future clinical trials.
Fichier principal
Vignette du fichier
Figures_Micheau.pdf (1.68 Mo) Télécharger le fichier
BJP_review_Micheau_2013.pdf (475.64 Ko) Télécharger le fichier
Origin Files produced by the author(s)
Origin Files produced by the author(s)

Dates and versions

inserm-00823459 , version 1 (01-05-2014)


  • HAL Id : inserm-00823459 , version 1


Olivier Micheau, Sarah Shirley, Florent Dufour. Death receptors as targets in cancer. 2014. ⟨inserm-00823459⟩
734 View
528 Download


Gmail Mastodon Facebook X LinkedIn More